Disclosed LabsHow to Get Retatrutide in 2026
Retatrutide isn’t FDA-approved yet — Phase 3 trials are still running. Here’s where the molecule actually comes from in 2026, what quality signals separate legitimate research-peptide vendors from the rest, and how the Disclosed Labs trust index ranks them.
Regulatory status: investigational
Retatrutide (LY3437943) is Eli Lilly’s investigational GLP-1 / GIP / glucagon triple-agonist. It is in Phase 3 trials as of 2026 and has not been approved for human use by the FDA. This guide is research-context only — Disclosed Labs publishes vendor and lab transparency data and does not provide medical advice or dosing recommendations.
The two paths people actually use
Because retatrutide isn’t an approved drug, there are effectively two supply routes in 2026, and one of them is substantially smaller than people realize:
Compounding pharmacies
Not really available. Compounding pharmacies can substitute approved drugs under shortage rules (e.g. compounded semaglutide during the Wegovy shortage). Retatrutide isn’t approved, so it’s not on the bulk drug substances list compounders can legally use. Any pharmacy claiming compounded retatrutide pens should be treated with extreme skepticism.
Research peptide vendors
Where it actually comes from. Lyophilized research-grade peptide in vials labeled “not for human consumption.” Sourced from contract synthesis labs (mostly overseas, a few US). Quality varies dramatically. The vendor trust grade is the single most useful filter.
What separates a legitimate vendor from the rest
Every active retatrutide vendor in the Disclosed Labs index publishes some kind of Certificate of Analysis. The difference is whether the COA actually verifies what’s in the vial.
A complete COA should include all five testing panels:
- Identity — mass-spec or LC-MS confirmation (full rigor) or HPLC retention-time match against a reference standard (lower rigor but still a real signal)
- HPLC purity % — chromatographic purity of the peptide
- Endotoxin— USP <85> (limulus amebocyte lysate test, EU/mg)
- Microbial safety — USP <61> (microbial enumeration) or USP <71> (sterility test)
- Heavy metals — ICP-MS panel (As, Cd, Hg, Pb minimum)
- Net peptide content — actual mg of peptide per vial (vs. label claim — labels often overstate by 20–40%)
Vendors who publish only an HPLC purity number are showing you roughly 20% of the picture. The Disclosed Labs trust score weights safety panel coverage at 40% specifically because the four non-purity panels are what distinguish a sample that’s the right molecule and safe to handle from a sample where you only know the active ingredient percentage.
Common COA red flags
Patterns the Disclosed Labs corpus surfaces repeatedly across untrustworthy vendors:
- Lot-number collisions across multiple unrelated “vendors” — strongly suggests a single upstream supplier white-labeled to many resellers. See live collisions on the Forgery Map.
- Suspiciously narrow purity variance — real HPLC results vary across batches. Every lot reporting 99.5–99.8% with near-zero std-dev is statistically anomalous and suggests fabricated or templated COAs.
- Google Sheets PDF metadata — legitimate labs use LIMS systems. A COA whose PDF metadata identifies the source application as Google Sheets, or whose title contains the word “Template,” is almost certainly not a real lab document.
- Bulk-generated PDF timestamps — when dozens of “historical” COAs covering test dates spanning months were all PDF-generated within the same minute, that’s an automated export from a spreadsheet, not lab-issued documentation.
- Lab signatories with no public footprint — real lab directors at ISO-accredited facilities have at least some public presence (LinkedIn, publications, conference talks).
Start from the trust index, not the vendor’s homepage
Disclosed Labs scores every peptide vendor we’ve indexed on their published COAs — avg HPLC purity, safety panel coverage, lab corroboration, and forgery flags — to produce a 0–100 composite and A–F letter grade. Vendors at grade F (and any vendor we’ve manually hidden for verifiable misconduct) don’t appear on the public leaderboard.
Related guides
TRIUMPH trial titration schedule and dosing math.
Pillar guide on peptide therapy — routes, costs, regulatory landscape, and how to start.
Exactly how Disclosed Labs computes vendor grades — weights, formulas, and what each panel signals.
Frequently asked questions
Is retatrutide available by prescription in 2026?
Not in approved form. Retatrutide (LY3437943) is Eli Lilly's investigational triple-agonist. As of 2026 it is in Phase 3 clinical trials (TRIUMPH-1, TRIUMPH-2, TRIUMPH-4) and has not received FDA approval. There is no branded prescription product. Compounding pharmacies cannot legally compound it the way they can compound semaglutide or tirzepatide during shortage windows — the active ingredient simply isn't on the approved-API list. Any retatrutide circulating in 2026 is research-grade material from third-party synthesis labs.
Where does retatrutide come from if it's not FDA-approved?
Research peptide vendors source retatrutide from contract synthesis labs — most commonly overseas custom peptide manufacturers (China, India, Eastern Europe) and a smaller number of US contract synthesis houses. The peptide is sold as a research chemical, lyophilized in vials, labeled 'for research use only — not for human consumption.' The legal framing matters: vendors selling research peptides are operating in a research-supply niche, not as drug retailers. None of this product chain is FDA-regulated for safety, purity, or accurate labeling.
How do I tell if a retatrutide vendor is legitimate?
The single most useful signal is whether they publish lot-specific Certificates of Analysis from a named, verifiable third-party lab — not just an HPLC purity screenshot. A complete COA should include: identity confirmation (mass spec or HPLC with retention-time match against a reference standard), HPLC purity %, endotoxin testing (USP <85>), microbial safety (USP <61> or <71>), heavy metals (ICP-MS), and net peptide content in mg per vial. Vendors who publish only a single purity number are showing you about 20% of the picture. The Disclosed Labs trust index scores every published COA on these dimensions — see /vendors for current rankings.
What are the red flags in a retatrutide COA?
Cluster of suspicious patterns we see often: (1) lot numbers that collide across multiple unrelated 'vendors' (suggests a single upstream supplier white-labeled to many resellers), (2) purity values clustered at 99.5–99.8% across every batch (real HPLC variance is wider — narrow clustering suggests rubber-stamping or fabricated COAs), (3) PDFs whose metadata identifies the document as a Google Sheets template (legitimate labs use LIMS systems, not spreadsheet exports), (4) lab signatories with zero LinkedIn or publication footprint, (5) batches whose claimed test dates span months but whose PDF creation timestamps cluster within minutes of each other (a script-generated COA pile, not lab-issued documents).
How much does research-grade retatrutide cost in 2026?
Pricing varies by vendor. Live cross-vendor data in the Disclosed Labs index shows 10mg vials currently ranging roughly $45–$150, with most listings between $65 and $100. Bulk packs (5–10 vials) can bring the per-vial price lower. Trust grade does not perfectly predict price — both A/B and C/D vendors appear across the price range. The live, sorted comparison is at /prices/retatrutide and updates daily.
Is it legal to buy retatrutide in the US?
Buying research peptides for research use is generally legal at the purchase stage — research chemicals are sold under 'not for human consumption' labels and are not scheduled substances. Using them on yourself crosses into a gray zone the FDA does not currently prosecute end users for but does not endorse. Importing personal quantities is subject to FDA discretion at the border. Disclosed Labs publishes vendor trust grades and COA data for research transparency purposes; we do not provide medical advice or dosing recommendations.
Are compounded retatrutide pens or syringes available?
No legitimate compounding pharmacy is producing patient-ready retatrutide as of 2026 because the active ingredient is not on the FDA bulk drug substances list and there is no approved drug experiencing a shortage that compounders could substitute for. Any pharmacy offering 'compounded retatrutide injection pens' should be treated with extreme skepticism — that's outside the legal framework for compounding under section 503A or 503B of the FD&C Act. Tirzepatide compounding pharmacies are a separate, FDA-recognized category during the shortage window for that drug.